Price T Rowe Associates Inc Heron Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
A detailed history of Price T Rowe Associates Inc transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 29,922 shares of HRTX stock, worth $85,876. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,922
Previous 25,931
15.39%
Holding current value
$85,876
Previous $45,000
84.44%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding HRTX
# of Institutions
168Shares Held
119MCall Options Held
151KPut Options Held
103K-
Rubric Capital Management LP New York, NY26.7MShares$76.7 Million2.52% of portfolio
-
Orbimed Advisors LLC San Diego, CA10.1MShares$29 Million0.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.11MShares$23.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$20.9 Million0.0% of portfolio
-
Velan Capital Investment Management LP Alpharetta, GA6.99MShares$20.1 Million21.7% of portfolio
About HERON THERAPEUTICS, INC.
- Ticker HRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 118,774,000
- Market Cap $341M
- Description
- Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...